Adenocarcinoma NSCLC is characterized of high prevalence of oncogenic driver mutations, with EGFR mutation rate of 27% and anaplastic lymphoma kinase (ALK) rearrangement rate of <8%.4 The gene discussed is ALK; the disease is non-small cell lung carcinoma.